Exondys 51 Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to lack of curative dmd therapies, historical reliance on supportive care, early antisense research, rare disease drug incentives, initial regulatory approvals.

The growth in the forecast period can be attributed to advancements in molecular genetics, expansion of personalized neuromuscular care, rising newborn screening initiatives, increased research funding for dmd, growing specialty neurology centers. Major trends in the forecast period include growth of exon skipping therapies, expansion of targeted dmd treatments, rising adoption of genetic based medicines, focus on slowing disease progression, increasing long term therapy management.

The increasing burden of genetic disorders is expected to drive the growth of the exondys 51 market in the coming years. Genetic disorders are conditions caused by abnormalities or mutations in an individual’s DNA or genetic material. The rising burden of these disorders is attributed to factors such as advancements in medical technology, demographic changes, and improvements in diagnosis and awareness. Exondys 51 (eteplirsen) treats genetic disorders by enabling exon 51 skipping in the dystrophin gene, allowing production of a functional, albeit shortened, dystrophin protein to slow muscle degeneration. For example, in July 2024, the National Health Service, a UK-based government department, reported that approximately 70,000 individuals in the UK are affected by muscular dystrophy (MD) or related conditions, with Duchenne MD being the most common form. Each year, around 100 boys are diagnosed with Duchenne MD, and approximately 2,500 people in the UK live with the condition at any given time. Therefore, the rising burden of genetic disorders is supporting the growth of the exondys 51 market.

Rising healthcare investments are also expected to propel the growth of the exondys 51 market. Healthcare investments involve the allocation of financial resources to entities, technologies, services, or innovations within the healthcare sector. Investments are increasing due to growing demand for chronic disease management from aging populations and funding for advanced technologies such as telemedicine to enhance healthcare delivery. For Exondys 51, healthcare investments support research, clinical trials, and technologies like exon-skipping, which enable treatment of Duchenne muscular dystrophy and improve patient access through supportive programs and infrastructure. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to 0.9% growth in 2022. Therefore, rising investments in healthcare are driving the growth of the exondys 51 market.

Major companies in the exondys 51 market are focusing on enhancing safety and refining patient selection, such as updating prescribing information for ELEVIDYS to mitigate liver-related risks and ensure proper patient eligibility. ELEVIDYS refers to Sarepta Therapeutics’ AAV-based micro-dystrophin gene therapy (delandistrogene moxeparvovec) designed to restore dystrophin expression in patients with Duchenne muscular dystrophy (DMD). For example, in November 2025, the U.S. FDA approved an updated label for ELEVIDYS, adding a boxed warning for acute serious liver injury and acute liver failure, and restricting use to ambulatory patients aged four years and older. The update mandates weekly liver-function testing for the first three months post-infusion, requires corticosteroid use before and after dosing, and advises patients to remain near a qualified healthcare facility for at least two months, all aimed at improving safety monitoring and patient outcomes.

Major companies operating in the exondys 51 market are Sarepta Therapeutics.

North America was the largest region in the exondys 51 market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the exondys 51 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the exondys 51 market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the exondys 51 market by increasing costs related to oligonucleotide manufacturing, specialized raw materials, and global pharmaceutical logistics. These impacts are most pronounced in hospital pharmacy and specialty distribution channels, particularly in emerging markets reliant on imported genetic therapies. Elevated tariffs may affect treatment affordability and reimbursement timelines. However, tariffs are also driving investments in local manufacturing capabilities, technology transfer, and streamlined supply chains to support sustainable access to advanced therapies.

The exondys 51 market research report is one of a series of new reports that provides exondys 51 market statistics, including exondys 51 industry global market size, regional shares, competitors with a exondys 51 market share, detailed exondys 51 market segments, market trends and opportunities, and any further data you may need to thrive in the exondys 51 industry. This exondys 51 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Exondys 51 (eteplirsen) is a medication used to treat Duchenne muscular dystrophy (DMD) by promoting exon-skipping of the dystrophin gene, enabling the production of a functional, though shortened, dystrophin protein. It specifically skips over exon 51 of the dystrophin gene, allowing the synthesis of a truncated but functional version of the protein.

The main types of indications for exondys 51 are relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), and other forms of multiple sclerosis. Relapsing-remitting multiple sclerosis (RRMS) is the most common type, marked by clearly defined relapses or attacks of neurological symptoms. It is distributed through hospital pharmacies, specialty pharmacies, and online pharmacies, with applications including subcutaneous injection, long-term disease management, and prophylactic use.

The exondys 51 market consists of sales of products including golodirsen (Vyondys 53), viltolarsen (Viltepso), and casimersen (Amondys 45). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.